Tertiary cytoreduction for recurrence of ovarian CANCER patients after intraperitoneal chemotherapy
The present study showed that IP chemotherapy does not represent an obstacle to surgery in ROC patients. The surgery after IP is feasible. No significant differences in terms of complications and outcomes were observed in the two groups.
Authors
- Giorgio Bogani (ORCID: https://orcid.org/0000-0001-8373-8569)
- Ludovico Muzii (ORCID: https://orcid.org/0000-0001-7195-9583)
- Margherita Fischetti
- Tullio Golia D’Augè (ORCID: https://orcid.org/0000-0002-1018-3088)
- Federica Tomao (ORCID: https://orcid.org/0000-0002-9738-3102)
- Violante Di Donato (ORCID: https://orcid.org/0000-0002-9254-5790)
- Giusi Santangelo (ORCID: https://orcid.org/0000-0001-7917-035X)
- Innocenza Palaia (ORCID: https://orcid.org/0000-0003-2346-8696)
- Giorgia Perniola (ORCID: https://orcid.org/0000-0003-0321-9828)
- Pierluigi Benedetti Panici
- Enrico Ciminiello
Institutions
- Policlinico Umberto I (IT)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
Publication Details
- Journal
- Frontiers in Medicine
- Published
- 2025-11-28
- DOI
- https://doi.org/10.3389/fmed.2025.1691155
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00